Back
Compare AU
Compare QUAL vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the MSCI Global 'Quality' (ex-AUS) (QUAL) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
QUAL | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,400 | 73 |
Median incremental investment | $993.50 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,562.94 | $1,696.50 |
Average age group | > 35 | > 35 |
Key Summary
QUAL | CURE | |
|---|---|---|
Strategy | QUAL's key objective is to invest in high-quality companies that have outperformed the market over the long term compared to global equity benchmarks. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | NVIDIA Corp (6.28 %) Apple Inc (5.96 %) Microsoft Corp (4.96 %) | Avidity Biosciences Inc Ordinary Shares (2.45 %) Revolution Medicines Inc Ordinary Shares (2.36 %) Insmed Inc (2.14 %) |
Top 3 industries | Information Technology (44.94 %) Communication Services (29.45 %) Financials (8.21 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (77.74 %) Switzerland (4.98 %) United Kingdom of Great Britain and Northern Ireland (4.22 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.4 % | 0.45 % |
Key Summary
QUAL | CURE | |
|---|---|---|
Issuer | VanEck | Global X |
Tracking index | MSCI World ex Australia Quality Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.4 % | 0.45 % |
Price | $61.43 | $58.50 |
Size | $7.990 billion | $38.099 million |
10Y return | 214.06 % | N/A |
Annual distribution yield (5Y) | 2.05 % | 5.08 % |
Market | ASX | ASX |
First listed date | 31/10/2014 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
QUAL | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,400 | 73 |
Median incremental investment | $993.50 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,562.94 | $1,696.50 |
Average age group | > 35 | > 35 |
Pros and Cons
QUAL | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
QUAL | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |